{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:15:08Z","timestamp":1784121308942,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pooled data analysis from three phase I\/II larotrectinib clinical trials revealed that larotrectinib demonstrated rapid and durable disease control and a favorable safety profile for patients with neurotrophic-tropomyosin receptor kinase (<jats:italic>NTRK<\/jats:italic>) fusion positive thyroid carcinoma. Herein, we report the case of a patient with papillary thyroid carcinoma (PTC) and liver metastases who demonstrated a durable response to treatment with larotrectinib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 50-year-old female with PTC was referred to our hospital for postoperative observation. Computed tomography (CT) scan was performed to screen for distant metastasis, since thyroglobulin concentration increased gradually, and revealed multiple distant metastases, including multiple liver metastases. Radioactive iodine was administered at a dose of 100\u00a0mCi. However, uptake was observed only in the thyroid bed, and distant metastases had no avidity. As liver metastases progressed, lenvatinib (24\u00a0mg\/day) was initiated after confirmation of liver metastases by liver biopsy 9\u00a0years and 1\u00a0month after the initial referral to our hospital. Since the multiple metastases became refractory for lenvatinib, the OncoGuide\u2122 NCC Oncopanel System was performed, and the <jats:italic>SQSTM1\u2013NTRK1<\/jats:italic> gene fusion was confirmed. Larotrectinib was subsequently administered at a dose of 200\u00a0mg\/day. The CT before the initiation of larotrectinib showed multiple liver metastases with a maximum diameter of 48\u00a0mm. The first CT evaluation at 1\u00a0month after the initiation of larotrectinib treatment showed that the tumor volume was reduced by 28% in the RECIST 1.1 criteria. After 3\u00a0months of larotrectinib treatment, a 38% reduction in the tumor volume was achieved as the best clinical response. The only side effect was grade 1 myalgia. At 12\u00a0months after the initiation of larotrectinib treatment, none of the lesions had progressed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, larotrectinib demonstrated effective antitumor activity against liver metastases of PTC, a relatively rare site of distant metastasis. Furthermore, the efficacy of larotrectinib was maintained, even though the patient had a history of multi-tyrosine kinase inhibitor treatment and a relatively infrequent fusion gene, <jats:italic>SQSTM1\u2013NTRK1<\/jats:italic>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40792-024-01971-1","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T03:31:32Z","timestamp":1721187092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Larotrectinib efficacy for liver metastases in papillary thyroid carcinoma patient harboring SQSTM1\u2013NTRK1 fusion"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-3529","authenticated-orcid":false,"given":"Haruhiko","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"1971_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"UC Megwalu","year":"2022","unstructured":"Megwalu UC, Moon PK. Thyroid cancer incidence and mortality. Trends in the United States: 2000\u20132018. Thyroid. 2022;32:560\u201370.","journal-title":"Thyroid"},{"key":"1971_CR2","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00268-023-06976-9","volume":"47","author":"H Yamazaki","year":"2023","unstructured":"Yamazaki H, Masudo K, Rino Y. Migration of risk classification between the JAES versus ATA guidelines for papillary thyroid carcinoma. World J Surg. 2023;47:1729\u201337.","journal-title":"World J Surg"},{"key":"1971_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319\u201328.","journal-title":"Lancet"},{"key":"1971_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621\u201330.","journal-title":"N Engl J Med"},{"key":"1971_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s12020-022-03183-9","volume":"78","author":"H Yamazaki","year":"2022","unstructured":"Yamazaki H, Iwasaki H, Masudo K, Toda S, Matsui A, Rino Y. Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer. Endocrine. 2022;78:543\u201351.","journal-title":"Endocrine"},{"key":"1971_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238207","volume":"15","author":"JH Yoon","year":"2022","unstructured":"Yoon JH, Jeon MJ, Kim M, Hong AR, Kim HK, Shin DY, et al. Unusual metastases from differentiated thyroid cancers: a multicenter study in Korea. PLoS ONE. 2022;15: e0238207.","journal-title":"PLoS ONE"},{"key":"1971_CR7","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","volume":"18","author":"AM Tsimberidou","year":"2012","unstructured":"Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18:6373\u201383.","journal-title":"Clin Cancer Res"},{"key":"1971_CR8","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S, Sudo T, Tamai I, Shiraishi Y, et al. C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov. 2022;12:2509\u201315.","journal-title":"Cancer Discov"},{"key":"1971_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","volume":"19","author":"TW Laetsch","year":"2018","unstructured":"Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study. Lancet Oncol. 2018;19:705\u201314.","journal-title":"Lancet Oncol"},{"key":"1971_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022;186:631\u201343.","journal-title":"Eur J Endocrinol"},{"key":"1971_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1971_CR12","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/cancers13081932","volume":"13","author":"B Pekova","year":"2021","unstructured":"Pekova B, Sykorova V, Mastnikova K, Vaclavikova E, Moravcova J, Vlcek P, et al. NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis. Cancers (Basel). 2021;13:1932.","journal-title":"Cancers (Basel)"},{"key":"1971_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","volume":"5","author":"A Vaishnavi","year":"2015","unstructured":"Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25\u201334.","journal-title":"Cancer Discov"},{"key":"1971_CR14","doi-asserted-by":"publisher","first-page":"14035","DOI":"10.1007\/s00432-023-05134-x","volume":"149","author":"VF Koehler","year":"2023","unstructured":"Koehler VF, Achterfeld J, Sandner N, Koch C, Wiegmann JP, Ivanyi P, et al. NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer. J Cancer Res Clin Oncol. 2023;149:14035\u201343.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1971_CR15","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41379-020-0574-4","volume":"33","author":"YH Chu","year":"2020","unstructured":"Chu YH, Dias-Santagata D, Farahani AA, Boyraz B, Faquin WC, Nos\u00e9 V, et al. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). Mod Pathol. 2020;33:2186\u201397.","journal-title":"Mod Pathol"},{"key":"1971_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340.","journal-title":"Lancet Oncol"},{"key":"1971_CR17","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/ccr3.3900","volume":"9","author":"F Pitoia","year":"2021","unstructured":"Pitoia F. Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion. Clin Case Rep. 2021;9:1905\u201312.","journal-title":"Clin Case Rep"},{"key":"1971_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1007\/s12105-021-01386-6","volume":"16","author":"M Saliba","year":"2022","unstructured":"Saliba M, Mohanty AS, Ho AL, Drilon A, Dogan S. Secretory carcinoma of the thyroid in a 49-year-old man treated with larotrectinib: protracted clinical course of disease despite the high-grade histologic features. Head Neck Pathol. 2022;16:612\u201320.","journal-title":"Head Neck Pathol"},{"key":"1971_CR19","doi-asserted-by":"publisher","first-page":"K5","DOI":"10.1530\/EJE-21-0509","volume":"186","author":"S Bargas","year":"2022","unstructured":"Bargas S, Mc Leer A, Mondet J, Chabre O, Laramas M. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion. Eur J Endocrinol. 2022;186:K5\u20138.","journal-title":"Eur J Endocrinol"},{"key":"1971_CR20","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1007\/s00268-018-4676-9","volume":"42","author":"Y Saito","year":"2018","unstructured":"Saito Y, Sugino K, Takami H, Matsuzu K, Uruno T, Ohkuwa K, et al. Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J Surg. 2018;42:3632\u20137.","journal-title":"World J Surg"},{"key":"1971_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1245\/s10434-014-4058-y","volume":"22","author":"A Madani","year":"2015","unstructured":"Madani A, Jozaghi Y, Tabah R, How J, Mitmaker E. Rare metastases of well-differentiated thyroid cancers: a systematic review. Ann Surg Oncol. 2015;22:460\u20136.","journal-title":"Ann Surg Oncol"},{"key":"1971_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","volume":"19","author":"LJ Jennings","year":"2017","unstructured":"Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017;19:341\u201365.","journal-title":"J Mol Diagn"},{"key":"1971_CR23","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1210\/jc.2008-0962","volume":"93","author":"WG Kim","year":"2008","unstructured":"Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2008;93:4683\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1971_CR24","doi-asserted-by":"publisher","first-page":"bvad084","DOI":"10.1210\/jendso\/bvad084","volume":"7","author":"D Sgr\u00f2","year":"2023","unstructured":"Sgr\u00f2 D, Rossi P, Piaggi P, Brancatella A, Lorusso L, Bottici V, et al. Significance of thyroglobulin autoantibodies in patients with thyroid cancer treated with lenvatinib. J Endocr Soc. 2023;7:bvad084.","journal-title":"J Endocr Soc"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01971-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40792-024-01971-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-024-01971-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T03:34:13Z","timestamp":1721187253000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-024-01971-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1186\/s40792-024-01971-1","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publications was obtained from the participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}